Glutamatergic agents for schizophrenia: current evidence and perspectives

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Schizophrenia treatment is hampered by a lack of etiological insight, limited biomarkers, and restricted therapeutic options focusing on dopaminergic pathways.
• Current antipsychotics inadequately address negative and cognitive symptoms, and treatment resistance often involves underutilization of clozapine.
• Emerging evidence points to extra-dopaminergic abnormalities, particularly in the glutamatergic system, as crucial in schizophrenia pathophysiology.

Purpose of the Study:

• To review the role of the glutamatergic system in schizophrenia and discuss challenges and future directions for glutamatergic-based therapies.
• To highlight the need for improved patient selection, focus on early disease stages and specific symptom domains (cognition, negative symptoms), and optimized dosing strategies for glutamatergic agents.

Main Methods:

• Review of existing literature on schizophrenia, dopaminergic and glutamatergic neurotransmission, and clinical trials of glutamatergic agents.
• Analysis of factors contributing to the limited success of recent glutamatergic drug trials in schizophrenia.

Main Results:

• Antidopaminergic antipsychotics and some mood stabilizers modulate the glutamatergic system.
• Recent trials of metabotropic glutamate receptor agonists and glycine uptake inhibitors for schizophrenia have failed.
• Key challenges include patient selection, focus on positive symptoms, late disease stages, and understanding dose-response relationships.

Conclusions:

• Glutamate's role in brain development suggests focusing research on the at-risk mental state or first-episode psychosis.
• Future clinical research should prioritize cognition and negative symptoms, utilizing monotherapy designs alongside augmentation strategies.
• Overcoming current challenges is essential for successfully leveraging glutamatergic agents in schizophrenia treatment.